1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7273-G000-401, NCT01007448
|
|
2.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 78 Sponsor: Pharmaceutical / Industry Protocol IDs: MOZ11809, NCT01164475
|
|
3.
|
Phase: Phase IV Type: Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Plerixafor-UF01, NCT01339572
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-A23465-21, NCT01569724
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 61 to 80 Sponsor: Other Protocol IDs: DSHNHL 2006-1B / ACT-2, BMBF GFVT 01014715, NCT00725231
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 72 Sponsor: NCI, Other Protocol IDs: 09-073, NCT00928018
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: EORTC-21081, EU-21020, EUDRACT-2009-011020-65, CELGENE-EORTC-21081, NCT01098656
|
|
10.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
|
|
11.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000702425, EORTC-21082, EU-21116, EUDRACT-2009-011021-13, NCT01386398
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: 2081-076, NCT01530581
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C25001, 2010-024215-14, NCT01578499
|
|
14.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: ISS-2007646931, NCT01642563
|
|
15.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 to 82 Sponsor: Other Protocol IDs: EudraCT 2012-000212-28, 24-169 ex 11/12, NCT01686594
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
17.
|
Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0110, NCT00019305
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: NHLBI Protocol IDs: NHLBI-02-H-0250, NCT00047060
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
21.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: NU 05H8, P30CA060553, NU-0310-101, LILLY-NU-05H8, NCT00369629
|
|
22.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 to 60 Sponsor: Other Protocol IDs: CIK#2/2007, NMRC/1097/2006, NCT00460694
|
|
23.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000544786, MAYO-LS0689, MAYO-07-000710, LS0689, NCT00474929
|
|
24.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
|
|
25.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ITL-001-HMC, NCT00558675
|